Share on LinkedInShare on LinkedIn

ARTICLE · 23 AUGUST 2017

SEC Director Of Investment Management Resigns

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

SEC Director of the Division of Investment Management, David Grim, will leave the agency next month after more than 20 years of public service.

United StatesFinance and Banking
Ann Kalodis
Ann Kalodis
Author LinkedIn connections

SEC Director of the Division of Investment Management, David Grim, will leave the agency next month after more than 20 years of public service. He leaves a legacy of regulatory policy reforms and legal guidance. The division oversees the $70-trillion asset management industry, which includes mutual funds; ETFs; closed-end funds; variable insurance products; business development companies and investment advisers.
Link To Article

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

SEC And CFTC Open Door To Tokenized Markets After Clarity Fails To Advance

The SEC and CFTC have issued coordinated regulatory relief measures that significantly advance crypto-based trading infrastructure in US markets, bypassing Congressional gridlock on the CLARITY Act. These orders establish new frameworks for tokenized securities venues and passive software providers, potentially reshaping how digital assets are traded and accessed in regulated markets.
United StatesFinance and Banking
K&L Gates
K&L Gates
Article

HRSA Announces Updated 340B Rebate Model Pilot Program, Limited To Drugs Subject To A Maximum Fair Price (MFP) For 2026 And 2027

The Health Resources and Services Administration has announced a revised 340B Rebate Model Pilot Program for drugs subject to Medicare's Maximum Fair Price, expanding eligibility to manufacturers with selected drugs for 2026 and 2027. The program introduces new data requirements, dispute resolution mechanisms, and stricter compliance monitoring while addressing stakeholder concerns about administrative burden and program integrity.
United StatesFinance and Banking
Hogan Lovells Cadwalader
Hogan Lovells Cadwalader
Article

Fintech Agrees To Acquire National Bank Partner For $590 Million

A publicly traded fintech company has announced a $590 million acquisition of its longtime national bank partner, marking a strategic shift from the traditional bank-partnership model to direct ownership of a national bank charter. The transaction, expected to close in the first half of 2027 pending regulatory approvals, would make the fintech a bank holding company while consolidating its banking activities and eliminating certain sponsor-bank fees. This deal represents a faster alternative to pursuing a d
United StatesFinance and Banking
Sheppard
Sheppard
Article

House Financial Services Committee Approves Legislation To Place CFPB Under Congressional Appropriations Process

The House Financial Services Committee on September 16 approved H.R. 10184, the Consumer Financial Protection Accountability and Reform Act of 2026, by a 28-21 vote. The legislation, sponsored by Rep. Andy Barr (R-Ky.), would make significant changes to the structure, funding, rulemaking, supervision, enforcement, and other authorities of the Consumer Financial Protection Bureau (CFPB).
United StatesFinance and Banking
Ballard Spahr LLP
Ballard Spahr LLP
Article

2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?

In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
GlobalFood, Drugs, Healthcare, Life Sciences
Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP